PD-L1 inhibition well-tolerated, active in metastatic RCC

By Shreeya Nanda, Senior medwireNews Reporter

The programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has a favourable toxicity profile and shows anti-tumour activity in previously treated patients with metastatic renal cell carcinoma (RCC), according to phase Ia trial findings.

David McDermott (Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA) and co-researchers say that atezolizumab is now being evaluated in combination with other therapies, such as bevacizumab, for first-line treatment in this patient population.

They add: “These trials will clarify the role for atezolizumab…in RCC and will explore the interplay between antiangiogenesis-targeted therapy and cancer immunotherapy.”

Of the 70 patients in the RCC cohort of an ongoing phase Ia dose-escalation and dose-expansion trial of atezolizumab, 90% had clear cell histology and 10% had non-clear cell disease. Initially patients were recruited irrespective of PD-L1 status, but subsequently only those harbouring tumours with at least 5% PD-L1–positive tumour infiltrating immune cells were enrolled.

Atezolizumab was administered intravenously every 3 weeks at doses ranging from 3–20 mg/kg, although one patient was given a flat 1200 mg dose. The median number of doses was 12, corresponding to a median treatment duration of 8 months.

Seventeen percent of study participants experienced a grade 3 treatment-related adverse event, with fatigue (4%) and anaemia (4%) being the most common, and 4% experienced a grade 3 immune-mediated adverse event. No side effects of grade 4 or 5 were observed in the study, but 4% of patients discontinued treatment as a result of a related toxic effect.

After a median follow-up of 23.9 months, progression-free survival and overall survival were a median of 5.6 and 28.9 months, respectively, for the 63 clear cell RCC patients assessed for survival outcomes. And an objective response per RECIST criteria was achieved by 15% of the 62 evaluable patients.

Interestingly, the objective response rate was an “impressive” 22% for the 18 patients with high Fuhrman grade and/or sarcomatoid features, both of which are generally associated with poor prognosis, reports the team.

Outcomes varied by PD-L1 expression, such that patients with less than 1% of PD-L1–positive tumour infiltrating immune cells had a shorter median overall survival and lower objective response rate than those with at least 1% of PD-L1–positive cells, at 28.8 months versus not reached and 9% versus 18%, respectively.

The researchers conclude in the Journal of Clinical Oncology: “Atezolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with metastatic RCC.”

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Research could lead to a new therapeutic option for patients with bladder cancer